J&J Hid Topamax Birth Defect Risks, Philly Jury Hears

Law360, Philadelphia (February 24, 2014, 5:55 PM EST) -- A Johnson & Johnson subsidiary failed to adequately warn parents about the risk of birth defects associated with the epilepsy and migraine drug Topamax, an attorney for the family of a 5-year-old boy born with a cleft palate told a Philadelphia jury on Monday.

Scott Love, an attorney with Clark Love & Hutson representing the family of 5-year-old Josiah Brown, told a state jury during opening arguments that the failure of J&J subsidiary Janssen Pharmaceuticals Inc. to provide information to doctors about the possibility of birth defects led Josiah's mother to continue taking Topamax to treat her migraines around the time...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!